Poster from another board, whom I believe is a solid long, says that due to P being a double blind trial that the interim data will only be whether the trial has encountered any adverse reactions to date that could halt further study and that no further data will be given as it could influence new trial members.

I personally don't think the extra 3 months or so would hurt to wait for topline data but would like to hear what others feel as to what kind of info we should expect from interim data report.

Can't believe there would have been that much PR on interim data in Q3 if it was just to say that all is going safely so far.

In Iceland on the northern coast and it is a spectacular, perfectly clear day, and hoping that the weather holds for another 7 hours or so without cloud cover so we have a small chance of seeing the Northern Lights.